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Introduction
The calcineurin inhibitor tacrolimus (FK506) is widely used for primary immunosuppression after renal transplantation. Tacrolimus has a narrow therapeutic index and large inter-individual variability, thereby requiring close therapeutic drug monitoring to maintain blood concentrations. It has been established that the area under the concentration-time curve (AUC) of tacrolimus correlates well with its trough blood levels, so therapeutic drug monitoring is performed using trough concentrations at the end of the twelve hour dosing interval (Masuda and Inui, 2006) . Racial differences in the pharmacokinetics of tacrolimus have been reported, namely that African Americans require higher doses of tacrolimus than Caucasians to achieve similar trough levels (Neylan, 1998) . This variation in the pharmacokinetics of tacrolimus among individuals has been attributed largely to the activity of both metabolizing enzymes (namely cytochrome P450s (CYPs) 3A4 and 3A5) and drug transporters including P-glycoprotein, encoded by the gene MDR1 (Masuda and Inui, 2006) . Both CYP3A4/5 and P-glycoprotein are expressed in the enterocytes of the small intestine and the hepatocytes of the liver where they act in concert to prevent absorption of the active drug into the systemic circulation from the gastrointestinal tract and to facilitate elimination of the drug from the body.
In clinical practice, we observed that Native American renal transplant patients require lower twice-daily doses of tacrolimus to attain similar trough levels in comparison to Caucasian patients. Because there are no pharmacokinetic studies of tacrolimus in this group, we investigated whether this clinical observation could be corroborated by pharmacokinetic differences between Native Americans and other ethnic and racial groups as reported in the literature.
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Materials and Methods
Study Cohort
After Institutional Review Board approval, we identified the study cohort by conducting a systematic chart review of adult Native American kidney transplant recipients on stable doses of tacrolimus for at least one month post-transplant. Hospital target trough levels are based on time since transplant: 10-12 ng/ml within the first month post-transplant, 8-10 ng/ml between the first and fourth months, and 5-8 ng/ml after four months. No patients were on medications, supplements, or foods known to interact with tacrolimus, such as anti-fungals, anti-epileptics, macrolide antibiotics, St. John's wort, or grapefruit.
Pharmacokinetic Study
We conducted a 12-hour pharmacokinetic profile for all patients. After an overnight fast, patients' morning tacrolimus dose was administered in capsules, and serial blood samples were drawn over the course of the dosing interval at times 0 (pre-dose), and 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose. EDTA whole blood samples were analyzed either fresh at room temperature or after being frozen at -80 ºC via whole blood immunoassay (Architect® tacrolimus in whole blood (Bazin et al., 2010) , Mayo Clinic Arizona, Phoenix, Arizona).
Pharmacokinetic & Statistical Analyses
Pharmacokinetic parameters were estimated using NONMEM (Version 7.1, Icon Development Solutions, Dublin, Ireland) using an empirical Bayesian approach. Linear onecompartment and two-compartment pharmacokinetic models with first-order absorption, with and without an absorptive lag time were evaluated based on the Objective Function Value 
Results & Discussion
Descriptive Analyses of Study Cohort
The baseline demographics for the 24 patients recruited to the study are shown in Table   1 . Family data demonstrated that all subjects had both parents and both sets of grandparents that belonged to an American Indian tribal group. Excluding only one patient who had been on therapy less than four months such that target trough levels were higher than for the rest of the patients (per hospital protocol), the average total daily tacrolimus dose was 2.54 ± 1.22 mg/day or 0.033 ± 0.021 mg/kg/day, and average trough levels were 6.53 ± 2.43 ng/ml. The pharmacokinetic parameters for this patient were within the range of the other patients'.
Pharmacokinetics
The pharmacokinetic profiles of all 24 patients are shown in Fig. 1 . A linear twocompartment model with first-order absorption and lag time was selected based on OFV. It has been previously noted that oral tacrolimus may be modeled with a lag time (Benkali et al., 2009 ).
Population parameter estimates and inter-individual variability estimates for oral clearance (CL/F), central compartment volume (V/F), inter-compartmental clearance (Q/F), steady state distribution volume (V ss /F), absorption rate (k a ), and absorption lag time (t lag ) were estimated in NONMEM, while mean parameter estimates and standard deviations were calculated from each individual's Bayesian estimates. The secondary pharmacokinetic parameters (peripheral compartment volume (V 2 ), alpha half life (t 1/2,α ), and beta half life (t 1/2,β )) were also calculated from each individual's Bayesian estimates. Pharmacokinetic parameters and variability estimates in our cohort are shown in Table 2 . cohort that had been on therapy for more than four months such that the target trough level was 5-8 ng/ml, CL/F was significantly associated with patients' total daily tacrolimus dose (linear regression p-value = 0.0013) such that each clearance increase of 1 L/hr is associated with a 0.138 mg increase in tacrolimus daily dose. Within all 24 patients, no other demographic characteristics (age, gender, weight, BMI, or total days on therapy) were associated with clearance or other pharmacokinetic parameters.
Comparison to Other Groups
A survey of the literature revealed a number of tacrolimus pharmacokinetic studies in various racial and ethnic groups. As shown in Table 3 , the oral clearance estimate in our Native American cohort (11.1 L/hr or 0.139 L/hr/kg) is approximately one-third of clearance values in other groups. Our analyses also corroborated the clinical observation that Native Americans require lower doses of tacrolimus: in a comparable study of Caucasian (~80%), African (~10%), and Oriental (~10%) renal transplant patients, the average tacrolimus dose at one year posttransplant was 0.076 mg/kg/day leading to an average trough concentration of 7.7 ± 1.6 ng/ml (Scholten et al., 2005) . In contrast, the average tacrolimus dose in our cohort was 0.033 mg/kg/day, approximately 40% of the non-Native American dose, but leads to a comparable average trough concentration of 6.53 ± 2.43 ng/ml. Our pharmacokinetic study reveals the clinically observed low dose of tacrolimus in Native American renal transplant patients is associated with a decreased oral tacrolimus clearance. This pharmacokinetic study is the first of its kind in Native American patients. There is scant information available on genetic and/or environmental characteristics unique to this ethnic group that affect pharmacokinetics in comparison to other, better-studied groups, and elucidation of these factors will provide information to further facilitate individualized drug treatment.
Polymorphisms in CYP3A5, namely the *3 reduced function variant, and polymorphisms in MDR1 (which encodes P-glycoprotein), including C3435T and G2677T/A, have been shown to affect tacrolimus pharmacokinetics (Masuda and Inui, 2006 ), but have not been evaluated in Native Americans. Additionally, clearance processes for a wide range of other drugs with narrow therapeutic indices, including chemotherapeutic agents, calcium channel antagonists, HIV protease inhibitors, hormones, and other immunosuppressives such as cyclosporine and sirolimus, are also mediated by CYP3A and P-glycoprotein (Zhang and Benet, 2001 ). Given these similarities, it is possible that Native American patients will also exhibit lower clearances for these classes of drugs, such that they may require lower doses to avoid the toxicities associated with narrow therapeutic index drugs. Future directions therefore include developing an understanding of these specific characteristics that may affect pharmacokinetics in Native American patients towards a goal of optimizing therapy and minimizing the reliance on therapeutic drug monitoring.
